Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Diagnostic and therapeutic challenges

Shatan Reddy¹, Jason Slakter, Thomas M Aaberg

¹Department of Ophthalmology, Manhattan Eye, Ear and Throat Hospital and NYU School of Medicine, New York, NY, USA.

Retina (Philadelphia, Pa.)

|June 15, 2007

Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Quality Improvement in Vitreoretinal Surgery: Single-Center Report on Utility of Routine Intravenous Fluids in Pars Plana Vitrectomy.

Journal of vitreoretinal diseases·2026

Same author

EFFICACY AND SAFETY OF THE PROPOSED BIOSIMILAR AFLIBERCEPT, SDZ-AFL, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: 52-Week Results From the Phase 3 Mylight Study: Erratum.

Retina (Philadelphia, Pa.)·2026

Same author

Long-term Outcomes of Faricimab in Previously Treated Neovascular Age-related Macular Degeneration.

Ophthalmic surgery, lasers & imaging retina·2026

Same author

Tyrosine kinase inhibitors for wet age-related macular degeneration: The current developmental landscape.

The Journal of pharmacology and experimental therapeutics·2026

Same author

Swept-Source OCT and OCT Angiography B-Scan Analysis of Inflammatory Retinal Vascular Changes: Quantitative and Qualitative Assessment.

Ophthalmology. Retina·2026

Same author

TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration.

Eye (London, England)·2025